Expand ESPR Menu
ESPR MENU

ESPR Latest Press Releases

-- December 9, 2025 --

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Globe Newswire 4:30 PM

-- November 21, 2025 --

Esperion Partner Otsuka Launches NEXLETOL in Japan for the Treatment of Hypercholesterolemia Globe Newswire 8:00 AM

-- November 19, 2025 --

Esperion to Participate in Piper Sandler 37th Annual Healthcare Conference Globe Newswire 8:00 AM

-- November 18, 2025 --

Esperion Partner HLS Therapeutics Announces Approval of NILEMDO for the Reduction of LDL-Cholesterol in Canadians at Risk of Cardiovascular Disease Globe Newswire 7:00 AM

-- November 10, 2025 --

Esperion Announces New Data from CLEAR Outcomes Highlighting Value of NEXLETOL (bempedoic acid) in Oral and Poster Presentations at the AHA Scientific Sessions 2025 Globe Newswire 8:00 AM

-- November 6, 2025 --

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Globe Newswire 4:30 PM
Esperion Reports Third Quarter 2025 Financial Results and Provides Business Update Globe Newswire 6:00 AM

-- November 4, 2025 --

Esperion Appoints Industry Veteran John Harlow as Chief Commercial Officer Globe Newswire 8:00 AM

-- November 3, 2025 --

Esperion to Participate in Jefferies Global Healthcare Conference - London Globe Newswire 8:00 AM

-- October 28, 2025 --

Esperion to Host Virtual Investor Key Opinion Leader Event Highlighting Significant Unmet Need in Statin Intolerance on Tuesday, November 11, 2025, at 2:00 p.m. ET. Globe Newswire 8:00 AM

-- October 27, 2025 --

Esperion Announces New Analyses from CLEAR Outcomes to be Presented at the American Heart Association (AHA) Scientific Sessions 2025 Globe Newswire 8:00 AM

-- October 23, 2025 --

Esperion to Report Third Quarter 2025 Financial Results on November 6 Globe Newswire 8:00 AM

-- October 16, 2025 --

Esperion Nominates ESP-2001 as Preclinical Development Candidate for Treatment of Primary Sclerosing Cholangitis Globe Newswire 8:00 AM

-- October 7, 2025 --

Esperion Announces Pricing of Public Offering of Common Stock Globe Newswire 9:29 PM
Esperion Announces Proposed Public Offering of Common Stock Globe Newswire 4:01 PM

-- October 3, 2025 --

Esperion Reaches Settlement Agreement with ANDA Filer, Dr. Reddy's Laboratories, Not to Market Generic Versions of NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) Prior to April 19, 2040 Globe Newswire 8:00 AM

-- September 19, 2025 --

Esperion Partner Otsuka Receives Regulatory Approval to Market NEXLETOL in Japan for the Treatment of Hypercholesterolemia Globe Newswire 8:00 AM

-- August 29, 2025 --

Esperion's Bempedoic Acid Receives Level 1a Recommendation in Updated ESC/EAS Guidelines for Management of Dyslipidaemias Globe Newswire 8:00 AM

-- August 26, 2025 --

Esperion to Participate in Upcoming September Investor Conferences Globe Newswire 8:00 AM

-- August 7, 2025 --

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Globe Newswire 5:30 PM

-- August 5, 2025 --

Esperion Reports Second Quarter 2025 Financial Results and Provides Business Update Globe Newswire 6:00 AM

-- July 22, 2025 --

Esperion to Report Second Quarter 2025 Financial Results on August 5 Globe Newswire 8:00 AM
Market Data Delayed 15 Minutes